Key result
Review explores genetic and inflammatory interplay in cardiomyopathies and highlights emerging targeted therapies.
Why the study?
Genetic variants that impair cardiac function or predispose to autoimmune diseases can influence the risk and severity of inflammatory heart diseases, prompting a review of the interplay between genetic susceptibility and myocardial inflammation.
This review summarizes the interplay between genetic susceptibility and active myocardial inflammation, exploring emerging therapeutic approaches targeting inflammation in genetic cardiomyopathies.
Does not support changes in cardiomyopathy management; leaves open whether inflammation-targeted therapies guided by genetics improve outcomes.
Genetic variants that impair cardiac function or predispose individuals to autoimmune diseases can influence both the risk and severity of inflammatory heart diseases, including lymphocytic myocarditis and cardiac sarcoidosis. We review recent clinical and experimental studies that describe the emerging interplay between genetic susceptibility and active myocardial inflammation. We summarize the current perspective on the mechanisms of inflammatory pathways and gene‐immune interactions, and explore the emerging therapeutic approaches aimed at targeting inflammation in genetic cardiomyopathies.
No takes yet. Share an insight, caveat, or question.
Peretto et al. (2026) conducted a review in Cardiomyopathies and inflammatory heart diseases. This review explores the interplay between genetic susceptibility and myocardial inflammation in cardiomyopathies, highlighting emerging therapeutic approaches targeting inflammatory pathways.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: